Report Detail
Global Prostate Cancer Nuclear Medicine Diagnostics Market 2024 by Company, Regions, Type and Application, Forecast to 2030
- RnM4606074 |
- 02 August, 2024 |
- Global |
- 114 Pages |
- GIR (Global Info Research) |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Prostate Cancer Nuclear Medicine Diagnostics market size was valued at USD 740.8 million in 2023 and is forecast to a readjusted size of USD 1457 million by 2030 with a CAGR of 10.1% during review period.
Nuclear medicine, a type of imaging that uses radioactive materials, is a useful tool to detect and also treat prostate cancer. It is a form of diagnostic imaging that helps radiologists determine the stage of cancer.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
The Global Info Research report includes an overview of the development of the Prostate Cancer Nuclear Medicine Diagnostics industry chain, the market status of Hospitals (SPECT, PET), Clinics (SPECT, PET), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Prostate Cancer Nuclear Medicine Diagnostics.
Regionally, the report analyzes the Prostate Cancer Nuclear Medicine Diagnostics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Prostate Cancer Nuclear Medicine Diagnostics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Prostate Cancer Nuclear Medicine Diagnostics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Prostate Cancer Nuclear Medicine Diagnostics industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., SPECT, PET).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Prostate Cancer Nuclear Medicine Diagnostics market.
Regional Analysis: The report involves examining the Prostate Cancer Nuclear Medicine Diagnostics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Prostate Cancer Nuclear Medicine Diagnostics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Prostate Cancer Nuclear Medicine Diagnostics:
Company Analysis: Report covers individual Prostate Cancer Nuclear Medicine Diagnostics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Prostate Cancer Nuclear Medicine Diagnostics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals, Clinics).
Technology Analysis: Report covers specific technologies relevant to Prostate Cancer Nuclear Medicine Diagnostics. It assesses the current state, advancements, and potential future developments in Prostate Cancer Nuclear Medicine Diagnostics areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Prostate Cancer Nuclear Medicine Diagnostics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Prostate Cancer Nuclear Medicine Diagnostics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
SPECT
PET
Market segment by Application
Hospitals
Clinics
Others
Market segment by players, this report covers
Blue Earth Diagnostics
PETNET Solutions
Cardinal Health
Lantheus Medical Imaging
Jubilant Pharma
NCM-USA
Progenics Pharma
Telix Pharma
ImaginAb
Theragnostics
Novartis
Alliance Medical
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Prostate Cancer Nuclear Medicine Diagnostics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Prostate Cancer Nuclear Medicine Diagnostics, with revenue, gross margin and global market share of Prostate Cancer Nuclear Medicine Diagnostics from 2019 to 2024.
Chapter 3, the Prostate Cancer Nuclear Medicine Diagnostics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Prostate Cancer Nuclear Medicine Diagnostics market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Prostate Cancer Nuclear Medicine Diagnostics.
Chapter 13, to describe Prostate Cancer Nuclear Medicine Diagnostics research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope of Prostate Cancer Nuclear Medicine Diagnostics
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Prostate Cancer Nuclear Medicine Diagnostics by Type
- 1.3.1 Overview: Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type: 2019 Versus 2023 Versus 2030
- 1.3.2 Global Prostate Cancer Nuclear Medicine Diagnostics Consumption Value Market Share by Type in 2023
- 1.3.3 SPECT
- 1.3.4 PET
- 1.4 Global Prostate Cancer Nuclear Medicine Diagnostics Market by Application
- 1.4.1 Overview: Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application: 2019 Versus 2023 Versus 2030
- 1.4.2 Hospitals
- 1.4.3 Clinics
- 1.4.4 Others
- 1.5 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size & Forecast
- 1.6 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast by Region
- 1.6.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
- 1.6.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region, (2019-2030)
- 1.6.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2019-2030)
- 1.6.4 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2019-2030)
- 1.6.5 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2019-2030)
- 1.6.6 South America Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2019-2030)
- 1.6.7 Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2019-2030)
2 Company Profiles
- 2.1 Blue Earth Diagnostics
- 2.1.1 Blue Earth Diagnostics Details
- 2.1.2 Blue Earth Diagnostics Major Business
- 2.1.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
- 2.1.4 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.1.5 Blue Earth Diagnostics Recent Developments and Future Plans
- 2.2 PETNET Solutions
- 2.2.1 PETNET Solutions Details
- 2.2.2 PETNET Solutions Major Business
- 2.2.3 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
- 2.2.4 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.2.5 PETNET Solutions Recent Developments and Future Plans
- 2.3 Cardinal Health
- 2.3.1 Cardinal Health Details
- 2.3.2 Cardinal Health Major Business
- 2.3.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
- 2.3.4 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.3.5 Cardinal Health Recent Developments and Future Plans
- 2.4 Lantheus Medical Imaging
- 2.4.1 Lantheus Medical Imaging Details
- 2.4.2 Lantheus Medical Imaging Major Business
- 2.4.3 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
- 2.4.4 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.4.5 Lantheus Medical Imaging Recent Developments and Future Plans
- 2.5 Jubilant Pharma
- 2.5.1 Jubilant Pharma Details
- 2.5.2 Jubilant Pharma Major Business
- 2.5.3 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
- 2.5.4 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.5.5 Jubilant Pharma Recent Developments and Future Plans
- 2.6 NCM-USA
- 2.6.1 NCM-USA Details
- 2.6.2 NCM-USA Major Business
- 2.6.3 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
- 2.6.4 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.6.5 NCM-USA Recent Developments and Future Plans
- 2.7 Progenics Pharma
- 2.7.1 Progenics Pharma Details
- 2.7.2 Progenics Pharma Major Business
- 2.7.3 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
- 2.7.4 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.7.5 Progenics Pharma Recent Developments and Future Plans
- 2.8 Telix Pharma
- 2.8.1 Telix Pharma Details
- 2.8.2 Telix Pharma Major Business
- 2.8.3 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
- 2.8.4 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.8.5 Telix Pharma Recent Developments and Future Plans
- 2.9 ImaginAb
- 2.9.1 ImaginAb Details
- 2.9.2 ImaginAb Major Business
- 2.9.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
- 2.9.4 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.9.5 ImaginAb Recent Developments and Future Plans
- 2.10 Theragnostics
- 2.10.1 Theragnostics Details
- 2.10.2 Theragnostics Major Business
- 2.10.3 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
- 2.10.4 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.10.5 Theragnostics Recent Developments and Future Plans
- 2.11 Novartis
- 2.11.1 Novartis Details
- 2.11.2 Novartis Major Business
- 2.11.3 Novartis Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
- 2.11.4 Novartis Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.11.5 Novartis Recent Developments and Future Plans
- 2.12 Alliance Medical
- 2.12.1 Alliance Medical Details
- 2.12.2 Alliance Medical Major Business
- 2.12.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
- 2.12.4 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
- 2.12.5 Alliance Medical Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue and Share by Players (2019-2024)
- 3.2 Market Share Analysis (2023)
- 3.2.1 Market Share of Prostate Cancer Nuclear Medicine Diagnostics by Company Revenue
- 3.2.2 Top 3 Prostate Cancer Nuclear Medicine Diagnostics Players Market Share in 2023
- 3.2.3 Top 6 Prostate Cancer Nuclear Medicine Diagnostics Players Market Share in 2023
- 3.3 Prostate Cancer Nuclear Medicine Diagnostics Market: Overall Company Footprint Analysis
- 3.3.1 Prostate Cancer Nuclear Medicine Diagnostics Market: Region Footprint
- 3.3.2 Prostate Cancer Nuclear Medicine Diagnostics Market: Company Product Type Footprint
- 3.3.3 Prostate Cancer Nuclear Medicine Diagnostics Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global Prostate Cancer Nuclear Medicine Diagnostics Consumption Value and Market Share by Type (2019-2024)
- 4.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Type (2025-2030)
5 Market Size Segment by Application
- 5.1 Global Prostate Cancer Nuclear Medicine Diagnostics Consumption Value Market Share by Application (2019-2024)
- 5.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Application (2025-2030)
6 North America
- 6.1 North America Prostate Cancer Nuclear Medicine Diagnostics Consumption Value by Type (2019-2030)
- 6.2 North America Prostate Cancer Nuclear Medicine Diagnostics Consumption Value by Application (2019-2030)
- 6.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
- 6.3.1 North America Prostate Cancer Nuclear Medicine Diagnostics Consumption Value by Country (2019-2030)
- 6.3.2 United States Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
- 6.3.3 Canada Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
- 6.3.4 Mexico Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
7 Europe
- 7.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Consumption Value by Type (2019-2030)
- 7.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Consumption Value by Application (2019-2030)
- 7.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
- 7.3.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Consumption Value by Country (2019-2030)
- 7.3.2 Germany Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
- 7.3.3 France Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
- 7.3.4 United Kingdom Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
- 7.3.5 Russia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
- 7.3.6 Italy Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
8 Asia-Pacific
- 8.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Consumption Value by Type (2019-2030)
- 8.2 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Consumption Value by Application (2019-2030)
- 8.3 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region
- 8.3.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Consumption Value by Region (2019-2030)
- 8.3.2 China Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
- 8.3.3 Japan Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
- 8.3.4 South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
- 8.3.5 India Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
- 8.3.6 Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
- 8.3.7 Australia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
9 South America
- 9.1 South America Prostate Cancer Nuclear Medicine Diagnostics Consumption Value by Type (2019-2030)
- 9.2 South America Prostate Cancer Nuclear Medicine Diagnostics Consumption Value by Application (2019-2030)
- 9.3 South America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
- 9.3.1 South America Prostate Cancer Nuclear Medicine Diagnostics Consumption Value by Country (2019-2030)
- 9.3.2 Brazil Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
- 9.3.3 Argentina Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
10 Middle East & Africa
- 10.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Consumption Value by Type (2019-2030)
- 10.2 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Consumption Value by Application (2019-2030)
- 10.3 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
- 10.3.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Consumption Value by Country (2019-2030)
- 10.3.2 Turkey Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
- 10.3.3 Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
- 10.3.4 UAE Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2019-2030)
11 Market Dynamics
- 11.1 Prostate Cancer Nuclear Medicine Diagnostics Market Drivers
- 11.2 Prostate Cancer Nuclear Medicine Diagnostics Market Restraints
- 11.3 Prostate Cancer Nuclear Medicine Diagnostics Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 Prostate Cancer Nuclear Medicine Diagnostics Industry Chain
- 12.2 Prostate Cancer Nuclear Medicine Diagnostics Upstream Analysis
- 12.3 Prostate Cancer Nuclear Medicine Diagnostics Midstream Analysis
- 12.4 Prostate Cancer Nuclear Medicine Diagnostics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Prostate Cancer Nuclear Medicine Diagnostics. Industry analysis & Market Report on Prostate Cancer Nuclear Medicine Diagnostics is a syndicated market report, published as Global Prostate Cancer Nuclear Medicine Diagnostics Market 2024 by Company, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Prostate Cancer Nuclear Medicine Diagnostics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
